StockVS

NASDAQ · Biotechnology · USD

Estrella Immunopharma, Inc. (ESLAW) Stock Analysis

Estrella Immunopharma, Inc. (ESLAW) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

ESLAW

$0.08

+$0.01 (+7.45%)

Last trade August 24, 2026

This is a derivative instrument — a warrant on Estrella Immunopharma, Inc. (ESLA) common stock.

Issuer fundamentals are shown on the issuer page, not here.

View ESLA →

Price History

Hover for the daily close. The dotted line marks the period open.

ESLAW Key Statistics

As of Aug 24, 2026
Trading
Open
$0.11
Previous Close
$0.07
Day's Range
0.08–0.08
52-Week Range
0.08–0.08
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.09

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Recent News

News provided by third-party sources. Not financial advice.

Related Biotechnology Stocks

View all Biotechnology stocks →

Popular Healthcare Stocks

View all Healthcare stocks →

About Estrella Immunopharma, Inc.

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.

Visit website →